纳武利尤单抗对比安慰剂治疗复发恶性间皮瘤:CONFIRM多中心双盲随机3期试验
这项在英国24家医院开展的3期试验纳入332例铂类化疗后进展的胸膜或腹膜恶性间皮瘤患者,按2:1随机接受纳武利尤单抗240 mg每2周或安慰剂。
要点
- 纳武利尤单抗显著改善铂类化疗后进展恶性间皮瘤的无进展生存期和总生存期。
- 3级及以上治疗相关不良事件以腹泻和输液反应常见,两组均无治疗相关死亡。
核心结论
- 纳武利尤单抗可能对一线治疗后进展的恶性间皮瘤患者有益。
研究设计与样本
- 多中心、安慰剂对照、双盲、平行组、随机3期试验,在英国24家医院开展。
- 纳入332例≥18岁、ECOG体能状态0或1、组织学确诊胸膜或腹膜间皮瘤、既往接受一线铂类化疗且有影像学进展证据的患者。
- 按2:1随机分配至纳武利尤单抗240 mg每2周静脉输注30分钟或安慰剂,直至疾病进展或最长12个月。
- 按上皮样与非上皮样组织学分层,随机区组大小3和6,参与者和治疗临床医生设盲。
- 共同主要终点为研究者评估的无进展生存期和总生存期,按治疗策略估计目标分析。
主要发现
- 纳武利尤单抗组最常见的3级及以上治疗相关不良事件为腹泻6例(3%)和输液相关反应6例(3%),安慰剂组分别为2例(2%)和无。
- 纳武利尤单抗组严重不良事件90例(41%),安慰剂组49例(44%)。
- 两组均无治疗相关死亡。
临床怎么用
- 对于一线铂类化疗后进展的胸膜或腹膜恶性间皮瘤患者,可考虑使用纳武利尤单抗。
- 用药方案为纳武利尤单抗240 mg每2周静脉输注30分钟,直至疾病进展或最长12个月。
- 治疗期间需关注腹泻和输液相关反应等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. METHODS: This was a multicentre, placebo-controlled, double-blind, parallel group, randomised, phase 3 trial done in 24 hospitals in the UK. Adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed pleural or peritoneal mesothelioma, who had received previous first-line platinum-based chemotherapy and had radiological evidence of disease progression, were randomly assigned (2:1) to receive nivolumab at a flat dose of 240 mg every 2 weeks over 30 min intravenously or placebo until disease progression or a maximum of 12 months. The randomisation sequence was generated within an interactive web response system (Alea); patients were stratified according to epithelioid versus non-epithelioid histology and were assigned in random block sizes of 3 and 6. Participants and treating clinicians were masked to group allocation. The co-primary endpoints were investigator-assessed progression-free survival and overall survival, analysed according to the treatment policy estimand (an equivalent of the intention-to-treat principle). All patients who were randomly assigned were included in the safety population, reported according to group allocation. This trial is registered with Clinicaltrials.gov, NCT03063450. FINDINGS: Between May 10, 2017, and March 30, 2020, 332 patients were recruited, of whom 221 (67%) were randomly assigned to the nivolumab group and 111 (33%) were assigned to the placebo group). Median follow-up was 11·6 months (IQR 7·2-16·8). Median progression-free survival was 3·0 months (95% CI 2·8-4·1) in the nivolumab group versus 1·8 months (1·4-2·6) in the placebo group (adjusted hazard ratio [HR] 0·67 [95% CI 0·53-0·85; p=0·0012). Median overall survival was 10·2 months (95% CI 8·5-12·1) in the nivolumab group versus 6·9 months (5·0-8·0) in the placebo group (adjusted HR 0·69 [95% CI 0·52-0·91]; p=0·0090). The most frequently reported grade 3 or worse treatment-related adverse events were diarrhoea (six [3%] of 221 in the nivolumab group vs two [2%] of 111 in the placebo group) and infusion-related reaction (six [3%] vs none). Serious adverse events occurred in 90 (41%) patients in the nivolumab group and 49 (44%) patients in the placebo group. There were no treatment-related deaths in either group. INTERPRETATION: Nivolumab represents a treatment that might be beneficial to patients with malignant mesothelioma who have progressed on first-line therapy. FUNDING: Stand up to Cancer-Cancer Research UK and Bristol Myers Squibb.
引用
- Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021. PMID: 34656227. doi:10.1016/S1470-2045(21)00471-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。